Sangamo BioScience (SGMO +5.2%) moves up after the company publishes research using zinc finger...


Sangamo BioScience (SGMO +5.2%) moves up after the company publishes research using zinc finger DNA-binding protein technology to insert a gene that will essentially "silence" the extra copy of a gene that causes Downs Syndrome. The procedure provides a model for studing the basic biology of Down syndrom, and could enable the development of drugs that can potentially rebalance the cellular processes and pathologies that are affected by the disorder.

From other sites
Comments (1)
  • Director one
    , contributor
    Comments (62) | Send Message
     
    Great science...........it will take 7 years to get thru FDA.......
    17 Jul 2013, 04:25 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs